Outcome of hospitalization for COVID-19 in patients with interstitial lung disease: an international multicenter study.
In: 1665 ; 1656, 2020
Online
academicJournal
Zugriff:
RATIONALE: The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. OBJECTIVES: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age, sex and comorbidity matched population. METHODS: An international multicenter audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death. MEASUREMENTS AND MAIN RESULTS: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and co-morbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 2.27, 1.39-3.71). CONCLUSIONS: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Titel: |
Outcome of hospitalization for COVID-19 in patients with interstitial lung disease: an international multicenter study.
|
---|---|
Autor/in / Beteiligte Person: | Drake, TM ; Docherty, AB ; Harrison, EM ; Quint, JK ; Adamali, H ; Agnew, S ; Babu, S ; Barber, CM ; Barratt, S ; Bendstrup, E ; Bianchi, S ; Castillo Villegas, D ; Chaudhuri, N ; Chua, F ; Coker, R ; Chang, W ; Crawshaw, A ; Crowley, LE ; Dosanjh, D ; Fiddler, CA ; Forrest, IA ; George, PM ; Gibbons, MA ; Groom, K ; Haney, S ; Hart, SP ; Heiden, E ; Henry, M ; Ho, L-P ; Hoyles, RK ; Hutchinson, J ; Hurley, K ; Jones, MG ; Jones, S ; Kokosi, M ; Kreuter, M ; Mackay, LS ; Mahendran, S ; Margaritopoulos, G ; Molina-Molina, M ; Molyneaux, PL ; O'Brien, A ; O'Reilly, K ; Packham, A ; Parfrey, H ; Poletti, V ; Porter, JC ; Renzoni, E ; Rivera-Ortega, P ; Russell, A-M ; Saini, G ; Spencer, LG ; Stella, GM ; Stone, H ; Sturney, S ; Thickett, D ; Thillai, M ; Wallis, T ; Ward, K ; Wells, AU ; West, A ; Wickremasinghe, M ; Woodhead, F ; Hearson, G ; Howard, L ; Baillie, JK ; Openshaw, PJM ; Semple, MG ; Stewart, I ; Jenkins, RG ; Investigators, ISARIC4C ; Action for Pulmonary Fibrosis ; National Institute for Health Research ; UK Research and Innovation |
Link: | |
Zeitschrift: | 1665 ; 1656, 2020 |
Veröffentlichung: | American Thoracic Society, 2020 |
Medientyp: | academicJournal |
ISSN: | 1073-449X (print) |
DOI: | 10.1164/rccm.202007-2794OC |
Schlagwort: |
|
Sonstiges: |
|